In our study, the majority of breast cancer treatments, including chemotherapy, anti-HER2 therapy, AIs, and TMX, were identified as risk factors for osteoporosis in younger women diagnosed with breast cancer before the age of 50. Here, ERBB2 is linked to breast cancer.